A股血液净化龙头企业威高血净(股份代码:603014)于2026年1月5日发布对威高普瑞的战略重组计划的草案。此举标志着中国医疗器械巨头的一次关键性战略跃进,业务版图将从临床血液净化治疗,延伸至技术同源的生物制药上游核心耗材领域。一、 不止于并购:一次基于“膜技术”同源性的战略卡位本次重组远非简单的资产整合。其深层逻辑在于,威高血净旨在复刻全球材料巨头日本旭化成(Asahi Kasei)的成功路径...
Source LinkA股血液净化龙头企业威高血净(股份代码:603014)于2026年1月5日发布对威高普瑞的战略重组计划的草案。此举标志着中国医疗器械巨头的一次关键性战略跃进,业务版图将从临床血液净化治疗,延伸至技术同源的生物制药上游核心耗材领域。一、 不止于并购:一次基于“膜技术”同源性的战略卡位本次重组远非简单的资产整合。其深层逻辑在于,威高血净旨在复刻全球材料巨头日本旭化成(Asahi Kasei)的成功路径...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.